04-08-2019 05:26 PM CET - Health & Medicine
Print

Peptide Cancer Vaccine Market | Global Growing Industry - TapImmune, Merck, BrightPath Biotherapeutics, Sellas, BioLife Science, Boston Biomedical, VAXON Biotech, Lytix Biopharma

Press release from: Coherent Market Insights - Biotechnology
Peptide Cancer Vaccine
Peptide Cancer Vaccine
Increasing prevalence of cancer and failure of conventional methods to treat the disease effectively have led to increasing demand for new immunotherapy-based therapy such as peptide vaccine. According to a National Cancer Institute, 2016, in the U.S., it was estimated that 16.8 million new cases of cancer were diagnosed with an approximate 595,690 deaths from the disease. The number of people with cancer is expected to rise to 19 million by 2024. Furthermore, the World Health Organization (WHO) reported around 14 million cases of cancer and 8.2 million deaths caused by the disease in 2012.

Get a Request Sample of Research Report @ www.coherentmarketinsights.com/insight/request-sample/1634

Furthermore, to cater to increasing demand for vaccines, manufacturers are also involved in mergers and acquisitions and new product launches in the peptide cancer vaccine market. For instance, in May 2018, Merck & Co. invested US$ 125 Million in Moderna Therapeutics. This expansion included partnering on mRNA-5671, Moderna’s mRNA KRAS cancer vaccine, and other shared antigen mRNA cancer vaccines. This vaccine includes an mRNA for four most commonly found KRAS mutations, which according to Moderna will cover most of the mutation that occur in non-small-cell lung cancer (NSCLC), colorectal cancer, and pancreatic cancer.

Furthermore, in November 2017, TapImmune Inc., a clinical-stage immune-oncology company with ongoing clinical trials in breast and ovarian cancer, announced that the company has enrolled the final patient in randomized Phase 2 clinical study for its novel T-cell vaccine candidate TPIV200 for treating triple-negative breast cancer (TNBC). More such clinical trials for peptide cancer vaccines are expected to boost growth of the global peptide cancer vaccine market in the near future.

Request for Customization of Research Report: www.coherentmarketinsights.com/insight/request-customizat...

North America market accounted for the largest share in the global peptide cancer vaccine market, followed by Europe market in 2016. This is attributed to presence of a high number of top pharmaceutical and biotech companies in this region, such as, Pfizer, Inc., Novartis, Merck, GlaxoSmithKline, Roche and many more. Moreover, the rising prevalence of cancer is also expected to foster the market of peptide cancer vaccine market in the near future.

Moreover, several pharmaceutical and biotechnological companies are focusing on expanding in Asia Pacific region to maximize the value on their R&D efforts as the Asia Pacific region provides better access to patients for clinical trials, and also provides lower cost operational efficiencies. Increasing government investment in research and development also fosters growth of the global peptide cancer vaccine market in Asia Pacific. For instance, in March 2011, the Korean government participated in the Korean National Enterprise for Clinical Trials, to advance the country’s infrastructure for conducting clinical trials, which is expected to launch new peptide cancer vaccine in the market.

Inquire about Discount on this Report @ www.coherentmarketinsights.com/insight/request-discount/1634

Major key players operating in the global peptide cancer vaccine market include, TapImmune, Merck, BrightPath Biotherapeutics, Sellas, BioLife Science, Boston Biomedical, VAXON Biotech, Lytix Biopharma, ISA Pharmaceuticals, Generex Biotechnology, OncoTherapy Science, Enzo Life Science, Antigen Express, Immatics Biotechnologies, Immatics, Immune Design, Immunomedics, Galena Biopharma, Generex Biotechnology Corporation, and Ultimovacs.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

1001 4th Ave,, #3200, Seattle, WA 98154

This release was published on openPR.
News-ID: 1693617 • Views: 411
More releasesMore releases

You can edit or delete your press release here: